Patent ID: 9023355
Filing Date: 2015-05-05
Classification: A61P,C07K,C12Q,G01N

Abstract:
1. A method of treating or reducing the likelihood of development of a renal disease comprising administering to a human subject expressing at least one pathogenic human APOL1 polypeptide comprising an S342G substitution, an I384M substitution, or a deletion removing amino acids N388 and Y389 a composition comprising an anti-APOL1 antibody or fragment thereof that specifically binds to the pathogenic APOL1 polypeptide, but does not specifically bind, or binds at a substantially greater dissociation constant, to a non-pathogenic APOL1 polypeptide, wherein said composition decreases a deleterious effect of the pathogenic APOL1 polypeptide.